A systematic review to assess the 'treat-and-extend' dosing regimen for neovascular age-related macular degeneration using ranibizumab.
about
Genetics of age-related macular degeneration (AMD).Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland.Efficacy and Safety of an Aflibercept Treat-and-Extend Regimen in Treatment-Naïve Patients with Macular Oedema Secondary to Central Retinal Vein Occlusion (CRVO): A Prospective 12-Month, Single-Arm, Multicentre TrialInitiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group
P2860
A systematic review to assess the 'treat-and-extend' dosing regimen for neovascular age-related macular degeneration using ranibizumab.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
A systematic review to assess ...... egeneration using ranibizumab.
@en
A systematic review to assess ...... egeneration using ranibizumab.
@nl
type
label
A systematic review to assess ...... egeneration using ranibizumab.
@en
A systematic review to assess ...... egeneration using ranibizumab.
@nl
prefLabel
A systematic review to assess ...... egeneration using ranibizumab.
@en
A systematic review to assess ...... egeneration using ranibizumab.
@nl
P2860
P50
P356
P1433
P1476
A systematic review to assess ...... degeneration using ranibizumab
@en
P2093
B L Stuart
H Almuhtaseb
P2860
P2888
P304
P356
10.1038/EYE.2017.67
P577
2017-05-05T00:00:00Z